AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03704779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal mindfulness activity program
Description: This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations.
Study NCT02352740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A form Arginine
Description: 3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
Study NCT02352740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B form Arginine
Description: 3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
Study NCT02684500 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
Study NCT03978871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset
Description: Growth emotion mindset induction
Study NCT03978871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Brain education
Study NCT00325533 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline BP Screening
Description: Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
Study NCT00325533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive 10-week Blood Pressure Screening
Description: Intensive 10-week Blood Pressure Screening
Study NCT00325533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive 10-week Blood Pressure Screening
Description: Intensive 10-week Blood Pressure Screening
Study NCT03640936 — intervention group
Intervention type: BEHAVIORAL
Intervention: Induced Sputum
Description: Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
Study NCT01664195 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Alfa
Description: Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
Study NCT01654146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC5 by intravenous infusion over 30-60 minutes
Study NCT01654146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 by intravenous infusion over 30-60 minutes
Study NCT01654146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC2 by intravenous infusion over 30-60 minutes
Study NCT01654146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2 by intravenous infusion over 3 hours
Study NCT01654146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 by intravenous infusion over 1 hour
Study NCT01840956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAVG
Description: HAVG is implanted into patients' arm.
Study NCT03569319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK-MED resource (baseline)
Description: The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline.
Study NCT03569319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK-MED resource (staged)
Description: This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian
Study NCT03569319 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention).
Study NCT02006966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic intravenous lidocaine infusion
Description: In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
Study NCT02006966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline infusion
Description: In group C, the patients receive same volume of normal saline
Study NCT03369756 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prontosan Wound Irrigation Solution and Prontosan Wound Gel
Description: Wound cleansing using Prontosan solution and gel
Study NCT00095290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril + Irbesartan
Description: Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
Study NCT00095290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramipril + Placebo
Description: Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
Study NCT06720233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951 tablets
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study NCT01573832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated client care group
Description: receives integrated client care for wound treatment
Study NCT03846921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory blood test
Description: Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
Study NCT00936377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
Study NCT00936377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for five days.
Study NCT02189694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop strategy
Description: Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
Study NCT02189694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop strategy
Description: Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
Study NCT02189694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
Study NCT01723956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
Study NCT04360148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: very-low-calorie-ketogenic-diet
Description: VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is \< 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.
Study NCT04360148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric-balanced-diet
Description: HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
Study NCT01723956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP
Description: The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
Study NCT01521728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
Study NCT01521728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Exercise
Description: Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
Study NCT01521728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/Range-of-Motion
Description: Stretching and range of motion exercise is widely accepted as a standard of care for ALS management.
Study NCT04485000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop
Description: The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
Study NCT04485000 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop
Description: The workshop is a day-long intervention delivered in 4 modules based on Cognitive Behavioural Therapy (CBT). The workshop covers PPD etiology, modifiable cognitive risk factors, cognitive skills, behavioural skills, problem solving, goal setting and action planning. Each participant is given a professionally designed manual to facilitate learning. Weekly reminder emails are sent for 6 weeks after the workshop completion to encourage practice. A list of PPD resources and a copy of the Canadian Treatment Guidelines for Postpartum Depression are provided.
Study NCT04647344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 plus Carboplatin and Pemetrexed
Description: Subjects receive AK104 15mg/kg intravenously (IV) plus pemetrexed 500 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV plus pemetrexed 500 mg/m\^2 IV Q3W until progression.
Study NCT01114802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Onward website + social network
Description: The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
Study NCT01114802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Onward website
Description: Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
Study NCT04647344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104 plus Carboplatin and paclitaxel
Description: Subjects receive AK104 15mg/kg intravenously (IV) plus paclitaxel 175 mg/m\^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK104 15mg/kg IV IV Q3W until progression.
Study NCT02371083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended timing of pessary care
Study NCT02429869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study NCT04310826 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary magnesium intervention
Study NCT04310826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Undergo video interviews
Study NCT04310826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone calls
Study NCT02445612 — intervention group
Intervention type: BIOLOGICAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
Study NCT01759381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Study NCT03873519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chromatic Environment
Description: Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.
Study NCT03873519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Room Orientation
Description: Room will be facing North or South
Study NCT03833388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOP1630 0.1% Ophthalmic Solution TID OU
Description: Bilateral ocular drug administration
Study NCT03833388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Description: Bilateral ocular drug administration
Study NCT01766011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study pre-term formula
Description: 24 kcal/fl oz pre-term formula for in-hospital use
Study NCT03387371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonics
Description: ultrasonic scalers
Study NCT03387371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey Curettes
Description: Spesific gracey curettes
Study NCT02532010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pacritinib
Description: Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
Study NCT02532010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
Study NCT02532010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
Study NCT03387371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gracey Curettes
Description: Spesific gracey curettes
Study NCT03387371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: 2940 nm wavelenght Er:YAG laser
Study NCT01230086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD Implantation without DFT testing
Description: Implantation
Study NCT01230086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limit of vulnerability testing
Description: Upper limit of vulnerability testing
Study NCT01230086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-wave shock with induction of ventricular fibrillation
Description: Traditional safety margin testing for defibrillation threshold
Study NCT01411150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Up to 30 grams daily creatine monohydrate
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT03907475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT01523782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
Study NCT05442502 — intervention group
Intervention type: PROCEDURE
Intervention: The overlap guiding tube(OGT) method
Description: The overlap guiding tube(OGT) is used to assist the anvil fork placed into the esophageal cavity.
Study NCT05442502 — intervention group
Intervention type: PROCEDURE
Intervention: The conventional overlap method
Description: After firing the stapler, two openings were converted into a single entry hole to create an end-to-side esophagojejunostomy, and the entry hole was closed with full-thickness running suture using barbed sutures intracorporeally.
Study NCT04445272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Treatment with Tocilizumab
Study NCT04504448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC664 capsules Single dose
Description: HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg
Study NCT01402115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polycan
Description: polycan 150 mg/d for 12 weeks
Study NCT04504448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HNC664 placebos Single dose
Description: HNC664 placebos single ascending doses,PO,Single dose, matching placebo
Study NCT04504448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC664 capsules FED
Description: HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）
Study NCT03377231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratamark®
Description: Film-forming dressing for the prevention and treatment of stretch marks.
Study NCT03193853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tak-228 & Tak-117
Description: Patients will receive 4mg oral TAK-228 and 200mg TAK-117 tablets until disease progression.
Study NCT03193853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin & Nab Paclitaxel
Description: following Tak-228 \& Tak-117 standard nab paclitaxel 175-220 mg/m2 plus cisplatin 60-75 mg/m2 infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
Study NCT03498430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
Study NCT03853174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training ET
Description: Endurance training were prformed. Intensity was gradually increased.
Study NCT03853174 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Training RT
Description: Resistance training were prformed. Intensity was gradually increased.
Study NCT01315938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept Active Treatment
Description: Participants will be treated with abatacept by intravenous infusions a total of seven times at week(s) 0, 2, 4, 8, 12, 16 and 20 weeks.
Study NCT01315938 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abatacept Delayed-Onset Treatment
Description: Participants will be treated with abatacept for 6 months and received a total of seven intravenous infusions at weeks 12, 14, 16, 20, 24, 28 and 32.
Study NCT03742518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical SM04554 solution
Description: Study medication application will be performed by the individual subject at approximately the same time each day.
Study NCT01402115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150mg/d for 12 weeks